Why Grail Stock Popped Today

Grail stock rose 11.5% as investors bought the dip following the company's ASCO conference presentation. However, the Galleri multi-cancer early detection test failed its primary endpoint in a landmark NHS trial, failing to reduce late-stage cancer detection. The stock's recovery reflects a 'sell on the news' bounce, though investors remain uncertain about FDA approval and insurance coverage prospects. The test showed promising sensitivity for key cancers but needs additional data to secure coverage.